RxDoctor Payments DataLook up a doctor →

Jeffrey Trump, MD

Family Medicine · Hurricane, WVNPI 1023171360

Payments from drug & device makers

$8,390in general payments, 2019–2025

Across 491 payments — averaging $17.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$985
  • AstraZeneca$842
  • AbbVie$775
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$410
  • Bayer$407
  • plus $4K from 42 others

What the payments were for

  • Food & beverage$8,31999%
  • Education$711%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,390 in reported general payments places this provider in the 90th percentile of 843 family medicine providers in West Virginia.

See all family medicine providers in West Virginia

Medicare billing

Part B allowed, 2024
$54,893
Medicare patients
207
Services billed
587

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban87$87,266
OzempicSemaglutide51$75,563
MounjaroTirzepatide48$60,296
TrulicityDulaglutide47$59,849
FarxigaDapagliflozin Propanediol34$39,190
JardianceEmpagliflozin22$37,231
XareltoRivaroxaban18$19,218
TradjentaLinagliptin17$16,441
Breo ElliptaFluticasone/Vilanterol17$12,238
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate18$4,198
Rosuvastatin Calcium299$3,225
SynthroidLevothyroxine Sodium29$3,103
Levothyroxine Sodium280$3,099
Metoprolol Succinate195$2,895
Valsartan108$2,758

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$985$120,14595 claims
PfizerEliquis$251$87,26687 claims
Novo NordiskOzempic$1,128$75,56351 claims
Boehringer IngelheimJardiance, Tradjenta$367$53,67239 claims
AstraZenecaFarxiga$842$39,19034 claims
Johnson & JohnsonXarelto$209$19,21818 claims
GSKBreo Ellipta$129$12,23817 claims
AbbVieSynthroid$775$3,10329 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 843 family medicine providers in West Virginia.

Other family medicine in Hurricane

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →